Source 1primary paper2025MED
Toolkit/peptide-drug conjugates
peptide-drug conjugates
Also known as: PDCs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The same peptide can function as ... a structural component of peptide-drug conjugates (PDCs) ... Additionally, we summarize their application in peptide-drug conjugates (PDCs) ...
Usefulness & Problems
Why this is useful
Peptide-drug conjugates are described as constructs in which peptides serve as structural components for cancer diagnosis or therapy. The review treats them as one major peptide modality in oncology.; using peptides as structural components in oncology therapeutic constructs
Source:
Peptide-drug conjugates are described as constructs in which peptides serve as structural components for cancer diagnosis or therapy. The review treats them as one major peptide modality in oncology.
Source:
using peptides as structural components in oncology therapeutic constructs
Problem solved
They help deploy peptide specificity within multifunctional therapeutic platforms for precision oncology. The review frames them as part of efforts to improve precision and reduce toxicity.; supports peptide-enabled therapeutic design in cancer applications
Source:
They help deploy peptide specificity within multifunctional therapeutic platforms for precision oncology. The review frames them as part of efforts to improve precision and reduce toxicity.
Source:
supports peptide-enabled therapeutic design in cancer applications
Problem links
supports peptide-enabled therapeutic design in cancer applications
LiteratureThey help deploy peptide specificity within multifunctional therapeutic platforms for precision oncology. The review frames them as part of efforts to improve precision and reduce toxicity.
Source:
They help deploy peptide specificity within multifunctional therapeutic platforms for precision oncology. The review frames them as part of efforts to improve precision and reduce toxicity.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
molecular conjugationTechniques
Structural CharacterizationTarget processes
No target processes tagged yet.
Input: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
The abstract supports that these constructs depend on engineered peptides incorporated into conjugate systems. Specific linker, payload, or manufacturing requirements are not given in the provided text.; requires peptide engineering and management of translational barriers for clinical use
The abstract does not claim that PDCs alone overcome all translational barriers. It explicitly notes that major barriers to clinical use remain and need to be addressed.; major translational barriers to clinical use are discussed
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review covers therapeutic peptides as targeting ligands, active agents, peptide-drug conjugates, peptide-guided radionuclides, and cancer vaccines.
Firstly, we outline the main functional classes of therapeutic peptides, covering their use as targeting ligands and their roles as active agents ... Additionally, we summarize their application in peptide-drug conjugates (PDCs), peptide-guided radionuclides, and cancer vaccines ...
A single peptide can serve as a targeting ligand, cell-penetrating motif, therapeutic effector, or structural component of peptide-drug conjugates, nanoparticle systems, and radionuclide constructs.
The same peptide can function as a targeting ligand, a cell-penetrating motif, a therapeutic effector, or a structural component of peptide-drug conjugates (PDCs), nanoparticle (NP) systems, and radionuclide constructs.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug peptide-drug-conjugates
The same peptide can function as ... a structural component of peptide-drug conjugates (PDCs) ... Additionally, we summarize their application in peptide-drug conjugates (PDCs) ...
Source:
application scopesupports
The review covers therapeutic peptides as targeting ligands, active agents, peptide-drug conjugates, peptide-guided radionuclides, and cancer vaccines.
Firstly, we outline the main functional classes of therapeutic peptides, covering their use as targeting ligands and their roles as active agents ... Additionally, we summarize their application in peptide-drug conjugates (PDCs), peptide-guided radionuclides, and cancer vaccines ...
Source:
functional convergencesupports
A single peptide can serve as a targeting ligand, cell-penetrating motif, therapeutic effector, or structural component of peptide-drug conjugates, nanoparticle systems, and radionuclide constructs.
The same peptide can function as a targeting ligand, a cell-penetrating motif, a therapeutic effector, or a structural component of peptide-drug conjugates (PDCs), nanoparticle (NP) systems, and radionuclide constructs.
Source:
Comparisons
Source-stated alternatives
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Source:
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Source-backed strengths
presented as part of adaptable, multifunctional peptide engineering platforms
Source:
presented as part of adaptable, multifunctional peptide engineering platforms
Compared with peptide-based cancer vaccines
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of adaptable, multifunctional peptide engineering platforms.
Relative tradeoffs: major translational barriers to clinical use are discussed.
Source:
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Compared with peptide-guided radionuclides
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of adaptable, multifunctional peptide engineering platforms.
Relative tradeoffs: major translational barriers to clinical use are discussed.
Source:
Nearby peptide modalities mentioned in the same abstract include nanoparticle systems, peptide-guided radionuclides, cancer vaccines, targeting ligands, and active therapeutic peptides.
Ranked Citations
- 1.